TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7033578

Group type: EXPERIMENTAL
Intervention: Stepped Care (SC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Referred Care (RC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General US population
Number of subjects: 100
Study: 31631602

Group type: EXPERIMENTAL
Intervention: Continuous low-volume ventilation during CPB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-ventilation (Control)
Number of subjects: 60
Study: 28993940

Group type: EXPERIMENTAL
Intervention: SILCS diaphragm
Number of subjects: 115

Group type: COMPARATOR
Intervention: Prefilled applicator
Number of subjects: 115
Study: 26142452

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg orally twice daily
Number of subjects: 3408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3408
Study: 24145210

Group type: EXPERIMENTAL
Intervention: Optimism induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No optimism
Number of subjects: 0
Study: 22453323

Group type: EXPERIMENTAL
Intervention: Pessary treatment
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (pelvic floor muscle training and continence strategies)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 446
Study: 20708452

Group type: EXPERIMENTAL
Intervention: Qigong intervention (10 training sessions in 5 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waiting-list control group (n=40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Qigong intervention (in subgroup with somatosensoric tinnitus)
Number of subjects: 80
Study: 17692594

Group type: EXPERIMENTAL
Intervention: Incremental-fill/occlusal irradiation technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bulk-fill/transtooth irradiation method
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single shade translucent material
Number of subjects: 70
Study: 15866684

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/d
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/d
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Everolimus (both doses)
Number of subjects: 256
Study: 12145567

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study: 10221663

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg daily for 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg daily for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-diabetic control subjects
Number of subjects: 24
Study: 8567551

Group type: EXPERIMENTAL
Intervention: Upright cycle exercise at 60% VO2peak in warm environments (22 and 36 degrees C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Upright cycle exercise at 60% VO2peak
Number of subjects: 12
Study: 2142866

Group type: EXPERIMENTAL
Intervention: Continuous infusion of epidural sufentanil (5 micrograms/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous infusion of lumbar epidural morphine (0.5 mg/h)
Number of subjects: 40
Study: 673790

Group type: EXPERIMENTAL
Intervention: VM 26 (60 mg/m2), methyl‐C.C.N.U. (120 mg/m2) and 5 fluoro‐uracile
Number of subjects: 39

Group type: COMPARATOR
Intervention: B.C.G. (simultaneous application)
Number of subjects: 39
Study: 31516010

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg per day for six weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no metformin)
Number of subjects: 68
Study: 28689855

Group type: EXPERIMENTAL
Intervention: PlanYourLifespan.org (PYL)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 385
Study: 25218708

Group type: EXPERIMENTAL
Intervention: Ixabepilone (40 mg/m(2) every 21 days)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ixabepilone (40 mg/m(2) every 21 days) with cetuximab (400 mg/m(2) loading dose, followed by 250 mg/m(2) once weekly)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 79
Study: 24413659

Group type: EXPERIMENTAL
Intervention: MECALF (motivational enhancement and conditioning activity for leg function) intervention delivered by WOC nurses for 6 weeks.
Number of subjects: 21

Group type: COMPARATOR
Intervention: CALF (conditioning activities for lower leg function) provided by site staff (not WOC nurses).
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MECALF intervention
Number of subjects: 21
Study: 22549501

Group type: EXPERIMENTAL
Intervention: Limited-sampling strategy (LSS) using time points at C(1h)-C(2h)-C(4h)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Limited-sampling strategy (LSS) using time points at C(1h)-C(1.5h)-C(2h)-C(4h)
Number of subjects: 71
Study: 19201709

Group type: EXPERIMENTAL
Intervention: lab‐PM (portable monitoring in the laboratory)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: home‐PM (portable monitoring at home)
Number of subjects: 157

Group type: COMPARATOR
Intervention: PSG (polysomnography)
Number of subjects: 157
Study: 17288854

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard chemotherapy and pre-medication (group B)
Number of subjects: 100
Study: 15251161

Group type: EXPERIMENTAL
Intervention: Supplementation with vitamin C, vitamin E and selenium dissolved in a beverage
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High plasma concentrations of antioxidant micronutrients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reduced/oxidised vitamin C ratio
Number of subjects: 48
Study: 11136647

Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluoxetine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluoxetine monotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 28
Study: 10440302

Group type: EXPERIMENTAL
Intervention: Intravenous mitomycin (1.4 mg/m2) and fluorouracil (166.7 mg/m2) twice weekly for 3 weeks after surgery, and oral UFT (uracil plus tegafur, 300 mg daily) for 18 months
Number of subjects: 579

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 579
Study: 7759461

Group type: EXPERIMENTAL
Intervention: 2 million U/m2 rIFN‐alpha 2a (n = 4)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 7
Study: 2319018

Group type: EXPERIMENTAL
Intervention: econazole nitrate (Spectazole)
Number of subjects: 24

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 24
Study: 6108445

Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Combined vaccine and immunoglobulin
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Pseudomonas infection of burns
Number of subjects: 191
Study: 30456502

Group type: EXPERIMENTAL
Intervention: Robot-assisted right colectomy (RAC)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Laparoscopic-assisted right colectomy (LAC)
Number of subjects: 71
Study: 28575646

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) active-treatment group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Medication-only control group
Number of subjects: 48
Study: 24450301

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day for 12 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 23903032

Group type: EXPERIMENTAL
Intervention: Zembrin (25 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21780946

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 7392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7392
Study: 19300221

Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 0
Study: 17702958

Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of urokinase (UK)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 14671730

Group type: EXPERIMENTAL
Intervention: Hypothetical drug trial consent process
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Decisional capacity measurement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reasons for participation in research
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psychiatric symptoms
Number of subjects: 60
Study: 11464260

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/benazepril 10 mg
Number of subjects: 454

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 454

Group type: COMPARATOR
Intervention: Benazepril 10 mg
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 11416702

Group type: EXPERIMENTAL
Intervention: Reduction in alcohol intake (1 drink per day for women, 2 drinks per day for men)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular alcohol consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excessive alcohol intake
Number of subjects: 0
Study: 9234577

Group type: EXPERIMENTAL
Intervention: VICOP-B (idarubicin 8 mg/sqm)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: VICOP-B (idarubicin 10 mg/sqm)
Number of subjects: 104

Group type: COMPARATOR
Intervention: VACOP-B (doxorubicin 50 mg/sqm)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: VICOP-B (idarubicin)
Number of subjects: 104

Group type: COMPARATOR
Intervention: VACOP-B (doxorubicin)
Number of subjects: 104
Study: 8480832

Group type: EXPERIMENTAL
Intervention: Adjuvant buspirone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3607808

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Felodipine + Isosorbide 5‐mononitrate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 8
Study: 2125869

Group type: EXPERIMENTAL
Intervention: Combined acupuncture and medication (ear needling and body needling with half-dosage Innovar and 0.1% lidocaine for scalp infiltration)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Acupuncture plus 0.1% lidocaine
Number of subjects: 174

Group type: COMPARATOR
Intervention: Acupuncture plus normal saline
Number of subjects: 174

Group type: COMPARATOR
Intervention: 0.1% lidocaine alone
Number of subjects: 174
Study: 1099171

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31721112

Group type: EXPERIMENTAL
Intervention: Epidural corticosteroids, cerebrospinal fluid drainage, controlled vascular hypertension
Number of subjects: 50
Study: 31090748

Group type: EXPERIMENTAL
Intervention: Internal hexagon implants (IHC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: External hexagon implants (EHC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both IHC and EHC
Number of subjects: 20
Study: 27464593

Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg every 6 hours)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 26932695

Group type: EXPERIMENTAL
Intervention: EECP therapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham EECP therapy
Number of subjects: 99
Study: 24573688

Group type: EXPERIMENTAL
Intervention: Videos/software/internet
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Individualized streetside instruction
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 240
Study: 22463698

Group type: EXPERIMENTAL
Intervention: Platinum chromium-based everolimus-eluting stent (PtCr-EES)
Number of subjects: 3750

Group type: COMPARATOR
Intervention: Cobalt chromium-based zotarolimus-eluting stent (CoCr-ZES)
Number of subjects: 3750

Group type: EXPERIMENTAL
Intervention: Triplet antiplatelet therapy (TAT)
Number of subjects: 3750

Group type: COMPARATOR
Intervention: Double-dose antiplatelet therapy (DDAT)
Number of subjects: 3750
Study: 19116965

Group type: EXPERIMENTAL
Intervention: sequential monotherapy
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: step-up combination therapy starting with methotrexate
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: initial combination therapy including tapered high-dose prednisone
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: initial combination therapy with methotrexate and infliximab
Number of subjects: 508
Study: 18158044

Group type: EXPERIMENTAL
Intervention: High-pressure spray of 0.3 mL 2% lidocaine using the MadaJet Medical Injector
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional vasal block with three 1.7-mL ampules of mepivacaine using a 27-gauge needle
Number of subjects: 50
Study: 15193965

Group type: EXPERIMENTAL
Intervention: Psychotherapy group (short-term psychodynamic therapy)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (standardized glucocorticoid therapy)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Psychotherapy group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 11779284

Group type: EXPERIMENTAL
Intervention: Olanzapine cotherapy (5-20 mg/d)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo + mood-stabilizer (valproate or lithium)
Number of subjects: 344
Study: 9807607

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.0 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Suxamethonium 0.5 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Suxamethonium 0.25 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Suxamethonium 0.5 mg/kg or more
Number of subjects: 80
Study: 7621645

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg daily for 2 days)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ephedrine sulphate (40 mg daily for 2 days)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dexamethasone + Ephedrine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study: 2488093

Group type: EXPERIMENTAL
Intervention: Amiodarone infusion (10-20 mg/kg in saline infusion within 4 to 10 hours through a central vein)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Glucose-insulin-potassium (GIK) infusion (150-300 g of glucose, 25-50 IU of insulin, and 80-120 mEq of KCl in 1000 cc of water at a rate of 1.5-2.0 ml/g/hour)
Number of subjects: 319
Study: 320630

Group type: EXPERIMENTAL
Intervention: Naproxen-Sodium (NS) 1100 mg
Number of subjects: 10
Study: 30414606

Group type: EXPERIMENTAL
Intervention: Touch Surgery (TS) app
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional paper-based learning program
Number of subjects: 12
Study: 28012682

Group type: EXPERIMENTAL
Intervention: AD risk assessments with genotype results
Number of subjects: 79

Group type: COMPARATOR
Intervention: AD risk assessments without genotype results
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Disclosure of ε4 positive results
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Disclosure of ε4 negative results
Number of subjects: 79
Study: 25830924

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS to the right secondary somatosensory cortex (S2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High-frequency rTMS to the sensorimotor cortex (S1/M1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 23301731

Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐IUS
Number of subjects: 571

Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 571
Study: 21829566

Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole‐cell and killed whole‐cell‐only oral cholera vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19588485

Group type: EXPERIMENTAL
Intervention: Baseline insulin levels (highest tertile)
Number of subjects: 5450

Group type: EXPERIMENTAL
Intervention: Baseline glucose levels
Number of subjects: 5450

Group type: EXPERIMENTAL
Intervention: Repeated measurements of serum insulin
Number of subjects: 5450
Study: 17349075

Group type: EXPERIMENTAL
Intervention: Blood orange juice (BOJ, 300 ml providing 150 mg vitamin C)
Number of subjects: 7

Group type: COMPARATOR
Intervention: C-drink (same amount of vitamin C)
Number of subjects: 7

Group type: COMPARATOR
Intervention: S-drink (sugars)
Number of subjects: 7
Study: 15065959

Group type: EXPERIMENTAL
Intervention: HIV-risk-reduction intervention
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Substance use reduction (SUR) intervention
Number of subjects: 408

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 408
Study: 11587503

Group type: EXPERIMENTAL
Intervention: Sustained release (SR) paracetamol (Panadol Extend)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Immediate release (IR) paracetamol (Panadol)
Number of subjects: 627
Study: 9848528

Group type: EXPERIMENTAL
Intervention: ePTFE membrane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: polylactic acid membrane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: polyglactin 910 membrane
Number of subjects: 8

Group type: COMPARATOR
Intervention: All membranes
Number of subjects: 8
Study: 8124836

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 2531605

Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg)
Number of subjects: 10
Study: 1094945

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 0
Study: 31697242

Group type: EXPERIMENTAL
Intervention: Electronic alcohol screening and brief intervention via email
Number of subjects: 0
Study: 30261963

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 128

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 128
Study: 27802250

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 24465671

Group type: EXPERIMENTAL
Intervention: Daily repetitive training using the rubber hand illusion paradigm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep after training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wakefulness after training
Number of subjects: 0
Study: 22179931

Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 600 mg
Number of subjects: 136

Group type: COMPARATOR
Intervention: bupivacaine HCl 200 mg
Number of subjects: 136
Study: 19334061

Group type: COMPARATOR
Intervention: MRI treatment effects
Number of subjects: 6591

Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 6591
Study: 17229229

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg (group K)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg (group G)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg + Granisetron 1.5 mg (group KG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (saline, group P)
Number of subjects: 160
Study: 14991494

Group type: EXPERIMENTAL
Intervention: Patients with three or more adenomas with at least one located on the proximal colon
Number of subjects: 552

Group type: COMPARATOR
Intervention: Patients with one or two adenomas on the distal colon
Number of subjects: 552
Study: 11665964

Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisolone, methotrexate, and sulfasalazine)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Baseline damage, swelling, or pain in a joint
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Swelling score (range 0‐2)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Sharp scale (range 0‐8 per joint)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pain scale (range 0‐3)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Mean pain and swelling scores over the year
Number of subjects: 155
Study: 9680497

Group type: EXPERIMENTAL
Intervention: High salt intake (220 mmol/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low salt intake (40 mmol/day)
Number of subjects: 18
Study: 7863948

Group type: EXPERIMENTAL
Intervention: MR imaging with primary criteria of cortical breakdown, replacement of bone marrow fat, or gadopentetate dimeglumine enhancement
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Negative MR study
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Positive MR study
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gadolinium enhancement
Number of subjects: 22
Study: 2573147

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rioprostil 100 micrograms b.i.d. (in rats)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1201644

Group type: EXPERIMENTAL
Intervention: Exogenous penta-gastrin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cholecystokinin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 14
Study: 30657406

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Cocaine group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Cocaine/Other Stimulant group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Other Stimulant group (primarily methamphetamine)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Overall construct validity
Number of subjects: 302
Study: 28781111

Group type: EXPERIMENTAL
Intervention: Initial biopsy prediction model
Number of subjects: 7963

Group type: EXPERIMENTAL
Intervention: Repeat biopsy prediction model
Number of subjects: 7963
Study: 25638351

Group type: EXPERIMENTAL
Intervention: Telehealth PTSD program, motivational interviewing-based smoking cessation curricula via telehealth device, weekly motivational interviewing counseling phone calls
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care including a telehealth PTSD program with a device that delivered PTSD information and in-home care management
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 120